Cardiometabolic & kidneySecondary analysis
Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis
- Secondary analysis of the SELECT randomised trial
- prespecified
Authors' conclusion
In SELECT, hsCRP data at baseline and in response to treatment with semaglutide support inflammation as a potential prognostic factor associated with cardiovascular risk in these generally well-treated patients with atherosclerotic cardiovascular disease and overweight or obesity but not diabetes.
Study context
- Population
- Patients with known atherosclerotic CVD and overweight or obesity, without diabetesSELECT trial
- Participants
- 17,604 patients
- Comparison
- Semaglutide vs placebo
- Primary endpoint
- MACE:
- CV death
- Nonfatal MI
- Nonfatal stroke
- Follow-up
- Mean , 39.8 months
Primary result
As reported in the abstract
Baseline hsCRP and MACE
Further findings
- Change in hsCRP with semaglutide · 104 weeks
- −37.8%
Change in hsCRP with semaglutide · 104 weeks
- Semaglutide reduced major adverse cardiovascular events (MACE) risk across all hsCRP subgroups
hsCRP reduction and weight loss
- Greater hsCRP reductions associated with greater weight loss, but preceded major weight loss (evident by 4 and 8 weeks) and occurred without weight loss
- hsCRP changes independent of LDL-C, statin use and atherosclerotic CVD entry criteria
- hsCRP reductions prognostic of decreased MACE risk
Original publication
Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation. Published 18 August 2026. doi:10.1161/circulationaha.125.074482
Summarised from the published abstract; every number is checked against it